MARK4 Antibody

Western Blot: MARK4 Antibody [NB100-1013] - Staining of U251 cell lysate (35 ug protein in RIPA buffer). Antibody at 1 ug/mL. Detected by chemiluminescence.

Flow Cytometry: MARK4 Antibody [NB100-1013] - Flow cytometric analysis of paraformaldehyde fixed A431 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.

Western Blot: MARK4 Antibody [NB100-1013] - Staining of Human Cerebellum lysate (A) + peptide (B), Mouse Brain lysate (C) + peptide (D) (35 ug protein in RIPA buffer). Antibody at 0.3 ug/mL. Detected by chemiluminescence.

• Reactivity: Hu, Mu
• Applications: WB, ELISA, Flow
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: 0.5 mg/ml

MARK4 Antibody Summary

• Immunogen: Peptide with sequence IKRKPPPGCSDSPGV corresponding to C-Terminus according to NP_113605.2.
• Specificity: This antibody is expected to recognize the reported long isoform 1 (NP_113605.2) only.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: MARK4
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 10 ug/mL
  • Peptide ELISA Detection limit 1:128000
  • Western Blot 0.3 - 1 ug/mL
• Control:

  MARK4 Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for MARK4 Antibody

• EC 2.7.11
• EC 2.7.11.1
• FLJ12177
• FLJ90097
• KIAA1860MARK4L
• MAP/microtubule affinity-regulating kinase 4
• MAP/microtubule affinity-regulating kinase like 1
• MAP/microtubule affinity-regulating kinase-like 1
• MARK4 serine/threonine protein kinase
• MARKL1L
• MARKL1MARK4S
• Nbla00650

Background

MARK4 contains an N terminal serine/threonine kinase domain, a central ubiquitin associated domain, and a C terminal KA1 associated kinase domain. RT PCR analysis detects upregulated expression of the gene for MARK4 in nearly all clinical hepatocellular carcinoma cells. Northern blot analysis reveals ubiquitous expression of a 3.6kb transcript, with highest expression in testis. Immunofluorescence microscopy demonstrates homogeneous cytoplasmic expression. Colony forming assays show that MARK4 antisense reduces the growth of SNU475 cells. It has been suggested that MARK4 provides a growth advantage to cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for MARK4 Antibody (NB100-1013)(2)

Publications using NB100-1013

• Kato T, Satoh S, Okabe H et al. Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in hepatocellular carcinogenesis. Neoplasia 2001-01-01 [PMID: 11326310]
• Sultanakhmetov G, Limlingan S, Fukuchi A et al. Mark4 ablation attenuates the pathological phenotype in tauopathy model mice Research Square 2023-10-05 (In vitro, Mouse)

Bioinformatics

• Gene Symbol: MARK4
• Entrez:
  • 57787(Human)
• Uniprot:
  • NP_113605.(Human)